The aim of this study was to investigate the prognostic significance of standardized uptake value (SUV) on 18 fluorine-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma (NPC). Thirty-four patients who have histologically proven NPC and underwent 18 F-FDG PET/CT were included in this study. After 18 F-FDG PET/CT, all the patients received radiation therapy and 32 of them received concomitant weekly chemotherapy. The maximum SUV (SUV max ) at the primary tumor and the SUV max of the highest neck nodes were determined. The SUV max -T ranged from 5.00 to 30.80 (mean: 15.37 ± 6.10) and there was no difference between SUV max -T values for early and late stages (P = 0.99). The SUV max -N ranged from 3.10 to 23.80 (mean: 13.23 ± 5.76). There was no correlation between SUV max -T and SUV max -N (r = 0.111, P = 0.532). There was no difference between the SUV max -T and the positivity of neck lymph nodes (P = 0.169). The ability of SUV maks -N to predict stage was obtained by a receiver operating characteristic (ROC) analysis. The area under the curve is 0.856 and the best cut-off value is 7.88. There was a good correlation between SUV max -N and stage. While the mean SUV max -T for the alive patients was slightly lower than that for the dead (14.65 ± 5.58 vs. 20.30 ± 7.92, P = 0.061), the difference between the groups was not statistically significant. Furthermore, there was no statistically significant difference for SUV max -N between these two groups (P: 0.494). Cox-regression analysis showed that an increase in SUV max -T and SUV max -N was associated with death risk (relative risk [RR]: 1.13, P = 0.078 and RR: 1.052, P = 0.456, respectively). SUV max -T and SUV max -N were independent prognostic factors for survival in NPC patients. This will help the clinicians in choosing suitable candidates for more aggressive treatment modalities.
Introduction
Nasopharyngeal carcinoma (NPC) is one of the most common types of head and neck cancer with the greatest incidence of neck node and/or distant metastases. [1] [2] [3] NPC is radiosensitive, and 5-year overall survival, and disease-free survival rates of up to 70% can be obtained by the use of concurrent chemoradiotherapy. [4, 5] However, some disease recurrence may develop after treatment. [5, 6] For these reason, identification of prognostic factors that Prognostic Significance of Standardized Uptake Value on 18 Fluorine-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Nasopharyngeal Carcinoma more accurately predict treatment outcome may help in determining which NPC patients might benefit from more aggressive treatment.
Eighteen fluorine-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) has been widely used in the initial diagnosis and staging of newly diagnosed NPC patients. F-18 FDG PET/CT can be used to assess glucose metabolic activity of tumors. [7] [8] [9] [10] [11] It provides useful information that cannot be obtained with other conventional imaging techniques. [9] [10] [11] The standardized uptake value (SUV) of F-18 FDG-PET is a quantified index of FDG uptake. Recent studies have focused on the relationship between F-18 FDG uptake and survival outcome in a variety of tumors. [12] [13] [14] [15] [16] SUV is an important prognostic factor for the head-and neck-cancer patients also. [12, 17, 18] In this study, we aimed to investigate the prognostic value of F-18 FDG PET/CT in patients with NPC. 
Materials and Methods

Positron emission tomography/computed tomography imaging
All patients were fasted for at least 6 h before F-18 FDG PET/CT imaging. All patients had glucose concentrations <150 mg/dL. Imaging was performed at 1 h after injection of 259-777 MBq (7-21 mCi) FDG using a dedicated full-ring PET/CT scanner (Biograph 6; Siemens Medical Systems, Erlangen, Germany). Nonenhanced CT images with a section width of 5 mm were acquired at 130 kV and 90 mA (mean). The PET scan was obtained immediately after the CT scan and 5-7 bed positions with an acquisition time of 4 min for each were used. CT-based attenuation corrections were performed.
For the PET images and reconstruction was carried out using an iterative reconstruction algorithm. After the standard PET/CT scan, additional images of the neck region were acquired with the patient's arms positioned alongside the body. PET/CT images were reviewed visually and semi-quantitatively with SUV by two experienced nuclear medicine physicians.
The maximal SUV in each region of interest was determined using the whole body attenuation corrected image [ Figure 1 ]. The maximum SUV (SUV max ) was defined as the highest activity concentration per injected dose per body weight after a correction for radioactive decay. The SUV max -T and SUV max -N were the SUV max at the primary tumor and the SUV max of the highest neck nodes, respectively. 
Treatment modality
Statistical analysis
The results are expressed as the mean values ± standard deviations. We used SPSS statistical software, version 11.5, (SPSS Inc., Chicago, Illinois, USA) for statistical analysis. T-test for independent samples was used to compare two situation categorical groups for a continuous date, Chi-square test for categorical data. Pearson's correlation analysis was used to analyze the correlations between SUV max -T and SUV max -N. The associations between SUV max -T and SUV max -N and risk of death were assessed with a Cox-regression analysis. Receiver operator curves were determined to assess the area under the curve and the optimal cutoff value for predicting stage. A P < 0.05 was considered statistically significant.
Results
Between March 2011 and August 2014, 34 patients with NPC diagnosis were included in the study. The characteristics of the patients are described in There was no correlation between SUV max -T and SUV max -N (r = 0.111, P = 0.532). The SUV max -T of patients with and without neck lymph nodes are shown in Table 2 . There was no difference between the SUV max -T and the positivity of neck lymph nodes (P = 0.169).
The ability of SUVmaks-N to predict stage was obtained by an ROC analysis. The area under the curve is 0.856 and the best cut-off value is 7.88 [ Figure 3 ]. There was a good correlation between SUV max -N and stage [ Table 3 ].
While the mean SUV max -T for the alive patients was slightly lower than that for the dead (14.65 ± 5.58 vs. 20.30 ± 7.92, P = 0.061), the difference between the groups was not statistically significant. Furthermore, there was no statistically significant difference for SUV max -N between these two groups (P = 0.494).
Cox-regression analysis showed that an increase in SUV max -T and SUV max -N was associated with death risk (relative risk [RR]: 1.13, P = 0.078 and RR: 1.052, P = 0.456, respectively).
Discussion
The efficacy of induction chemotherapy or dose escalation RT is investigating currently by many studies for improving survival of patients with advanced NPC. However, survival benefits of these treatments are still controversial because of their potential harms. [19] [20] [21] Regarding these items, it's important to identify the predictors associated with poor outcomes for choosing suitable candidates for such treatment modalities.
The 3-year and 5-year distant metastases free survival (DMFS) of NPC were 88.1% [22] and 79%. [23] In 2002, Lee et al. reported the 4-year DMFS was 66% without using PET in the staging. [24] Adding PET in the initial staging could reveal 10-20% of occult distant metastases. [8, 9] The better DMFS and OS in recent studies were likely because of the use of F-18 FDG PET in initial staging. Previous studies reported that the SUV of F-18 FDG PET represents a valuable prognosticator in patients with head-and neck-cancer. [12, 17, 18] NPC patients with a lower SUV max (SUV max <8.0) were found to had a significantly better disease-free survival. [25, 26] Similarly, our results showed lower SUV max -T value for the alive patients compared to that of deads. Additionally, the risk of death increases with an increase in SUV max -T and SUV max -N. Yang et al. reported that SUV max -T with a cut-off value of 15.6 and SUVmean-T of 4.7 were associated with local control, which was higher than previous studies (SUV max ranged from 6.48 to 12.0). [22, 27, 28] However, in our study, statistically significant cut-off value of SUV max could not be calculated.
Although high F-18 FDG uptake has been found to be related to tumor grade and aggressiveness [29, 30] and also with advanced disease stage, [17] we did not found any difference between SUV max -T values for early and late stages probably because of a limited number of the patients. However, we observed a good correlation between SUV max -N and the disease stage. Chan SC et al. suggested that SUV max value of lymph nodes is the most powerful factor in predicting regional node failure and retained its independent prognostic value in multivariable analysis. [28] In another study, SUV max of the node higher than that of the primary site was reported to be associated with poor prognosis. [25] The different PET parameters have specific prognostic features. Previous studies examined the prognostic value of metabolic tumor volume (MTV) and showed that high MTV values predict an increase in recurrence and death risk in patients with head and neck cancers. [28, 31] Since total lesion glycolysis (TLG) is a combination of SUV and MTV and represents both the volumetric and metabolic component of a tumor, it is better than SUV or MTV alone in predicting prognosis. [28] In the present study, MTV and TLG values could not be examined.
Near total of our patients were treated with both RT and CT. We observed excellent locoregional control. Among 34 patients, five were died because of toxicity (n = 3), disease progression (n = 1) and malnutrition (n = 1). Although combined RT and CT give excellent results, treatment toxicity is the leading cause of death in our patients. However, in literature, distant metastases are reported as the most significant reason of the treatment failure. Recently, The RT Oncology Group declared the results of a study regarding concurrent and adjuvant chemotherapy with bevacizumab. They proposed that this treatment is feasible and might delay the progression of the subclinical distant disease. [32] Hence, it is suggested that in patients with a high risk of distant failure, more aggressive systemic treatment could be considered which could be predicted by the stage, SUV max -T and SUV-max -N. [22] The major drawback of our study was the limited number of the patients. Although there were studies with similar patient number concerning prognostic factors of NPC patients in literature, further studies are needed with the larger patient population.
Conclusion
We demonstrated that SUV max -T value of the alive patients was lower than that of deads, and an increase in SUV max -T and SUV max -N was associated with death risk.
These data suggest that SUV max -T and SUV max -N were independent prognostic factors for survival in NPC patients. This will help the clinicians in choosing suitable candidates for more aggressive treatment modalities.
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